cdc-coteauxdegaronne
» » Federal and private roles in the development and provision of alglucerase therapy for Gaucher disease (Background paper)
eBook Federal and private roles in the development and provision of alglucerase therapy for Gaucher disease (Background paper) ePub

eBook Federal and private roles in the development and provision of alglucerase therapy for Gaucher disease (Background paper) ePub

  • ISBN: 0160381290
  • Subcategory: No category
  • Language: English
  • Publisher: For sale by the U.S. G.P.O., Supt. of Docs (1992)
  • Pages: 34
  • ePub book: 1277 kb
  • Fb2 book: 1868 kb
  • Other: lit mbr mobi lrf
  • Rating: 4.5
  • Votes: 205

Description

OTA Staff-Federal and Private Roles in the Development and Provision of Alglucerase Therapy for Gaucher Disease. Roger C. Herdman, Assistant Director Health and Life Sciences Division. Clyde J. Behney, Health Program Manager Project Staff.

Ethical Considerations for Enzyme Replacement Therapy in Neuronopathic Gaucher Disease . Elstein, Deborah; Abrahamov, Ayala; Zimran, Ari (1998-09). Related Items in Google Scholar.

We elicited utilities for Gaucher disease using a multimedia implementation of the time trade-off, standard . Federal and Private Roles in the Development and Provision of Alglucerase Therapy for Gaucher Disease: Background Paper. Office of Technology Assessment, US Congress.

We elicited utilities for Gaucher disease using a multimedia implementation of the time trade-off, standard gamble, and a conceptually different, largely untested approach, the risk-risk trade-off, from those who are healthy, those with a chronic illness and those with Gaucher disease. The risk-risk trade-off produced significantly lower utilities than the other two preference assessment methods and had the poorest test-retest reliability.

Federal and Private Roles in the Development and Provision of Alglucerase Therapy for Gaucher Disease (Washington: Office of Technology Assessment, 1992), by Alan M. Garber, Ann E. Clarke, Dana P. Goldman, and Michael E. Gluck (PDF files at Princeton). Items below (if any) are from related and broader terms.

I find it interesting that you do not reference OTA-BP-H-104 (Oc. 992) Federal and Private Roles in the Development and Provision of Alglucerase Therapy for Gaucher Disease. While the Brady/Gaucher story is told well, we are only seeing part of the story. This drug, and its later development by industy makes a wonderful case history and raises many ethical questions. I thought this was very well done. Easy to read and kept my interest. I especially like the terms in blue that are a mini glossary

At this point in time, enzyme replacement therapy for Gaucher disease appears both biochemically effective . Federal and private roles in the development and provision of alglucerase therapy for Gaucher disease.

At this point in time, enzyme replacement therapy for Gaucher disease appears both biochemically effective (patients 1-3, and 10) as well as clinically promising (patients 4 and 5), although these salutary responses have not been obtained consistently (patients 6-9). The discrepancy may be due to the method employed for the isolation of the enzyme. Enzyme replacement therapy for Gaucher disease. Ernest Beutler, Andrea Kay, +4 authors Bruce Rosenbloom.

Ill. OTA Staff-Federal and Private Roles in the Development and Provision of Alglucerase Therapy for Gaucher Disease.

In a background paper released today, OTA analyzes the the .

Alglucerase, marketed under the brand name Ceredase by Genzyme, In. a Massachusetts.

Federal and Private Roles in the Development and Provision of Alglucerase Therapy for Gaucher Disease. Diseases Familial Goiter PKU Gauchers ds Hemophyllia Mrthylmalonic aciduria Crigler-Najar syndrome. Hepatoprotective potential of crocin and curcumin against iron overload-induced biochemical alterations in rat. Schematic Representation of Extraction Procedure of Soya.